Gilead Sciences (NASDAQ:GILD) Releases FY 2022 Earnings Guidance

Gilead Sciences (NASDAQ:GILDGet Rating) updated its FY 2022 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $6.20-$6.70 for the period, compared to the consensus estimate of $6.50. The company issued revenue guidance of $23.80 billion-$24.30 billion, compared to the consensus revenue estimate of $24.48 billion.

A number of brokerages recently weighed in on GILD. BMO Capital Markets began coverage on shares of Gilead Sciences in a research note on Tuesday, March 8th. They issued a hold rating and a $65.00 price target on the stock. Argus raised shares of Gilead Sciences from a hold rating to a buy rating and set a $75.00 price target on the stock in a research note on Friday, January 28th. Barclays decreased their price target on shares of Gilead Sciences from $63.00 to $56.00 and set an underweight rating on the stock in a research note on Thursday, March 10th. StockNews.com began coverage on shares of Gilead Sciences in a research note on Thursday, March 31st. They issued a buy rating on the stock. Finally, Maxim Group decreased their price target on shares of Gilead Sciences from $88.00 to $84.00 in a research note on Thursday, February 3rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Hold and a consensus price target of $72.93.

Gilead Sciences stock opened at $61.68 on Tuesday. Gilead Sciences has a fifty-two week low of $57.19 and a fifty-two week high of $74.12. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.23 and a current ratio of 1.48. The firm has a 50 day moving average price of $60.57 and a 200 day moving average price of $65.40. The company has a market capitalization of $77.34 billion, a PE ratio of 17.23, a price-to-earnings-growth ratio of 0.43 and a beta of 0.38.

Gilead Sciences (NASDAQ:GILDGet Rating) last posted its earnings results on Thursday, April 28th. The biopharmaceutical company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.35. Gilead Sciences had a net margin of 16.43% and a return on equity of 44.98%. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.28 billion. During the same quarter last year, the firm earned $2.08 EPS. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. As a group, equities research analysts forecast that Gilead Sciences will post 6.62 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 29th. Investors of record on Wednesday, June 15th will be issued a $0.73 dividend. The ex-dividend date is Tuesday, June 14th. This represents a $2.92 annualized dividend and a yield of 4.73%. Gilead Sciences’s dividend payout ratio (DPR) is presently 81.56%.

In other news, EVP Brett A. Pletcher sold 1,691 shares of Gilead Sciences stock in a transaction on Wednesday, February 9th. The shares were sold at an average price of $63.89, for a total transaction of $108,037.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Brett A. Pletcher sold 3,634 shares of Gilead Sciences stock in a transaction on Friday, March 11th. The stock was sold at an average price of $58.24, for a total transaction of $211,644.16. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in GILD. Morgan Stanley lifted its position in shares of Gilead Sciences by 18.3% during the 2nd quarter. Morgan Stanley now owns 10,989,872 shares of the biopharmaceutical company’s stock worth $756,765,000 after purchasing an additional 1,702,366 shares during the last quarter. Toroso Investments LLC lifted its position in Gilead Sciences by 55.5% in the fourth quarter. Toroso Investments LLC now owns 62,542 shares of the biopharmaceutical company’s stock valued at $4,541,000 after acquiring an additional 22,313 shares during the last quarter. NewEdge Advisors LLC lifted its position in Gilead Sciences by 128.7% in the fourth quarter. NewEdge Advisors LLC now owns 31,127 shares of the biopharmaceutical company’s stock valued at $2,260,000 after acquiring an additional 17,516 shares during the last quarter. Paradigm Financial Partners LLC purchased a new stake in Gilead Sciences in the fourth quarter valued at $471,000. Finally, Titleist Asset Management LTD. purchased a new stake in Gilead Sciences in the fourth quarter valued at $208,000. 80.16% of the stock is owned by institutional investors and hedge funds.

About Gilead Sciences (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Featured Stories

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.